Characterization of the cholangiocarcinoma drug pemigatinib against fgfr gatekeeper mutants

HIGHLIGHTS

• who: Qianmeng Lin from the Department South University have published the article: Characterization of the cholangiocarcinoma drug pemigatinib against FGFR gatekeeper mutants, in the Journal: (JOURNAL) of 20/01/2022
• what: The authors aimed to explore the structural basis for the high potency of pemigatinib against FGFRs and predict the sensitivity to gatekeeper mutations. The authors performed kinase activity inhibition assays and cellular proliferation assays to demonstrate that pemigatinib is a potent and selective FGFR1-3 inhibitor.
• how: The detailed collection data are shown in Supplementary Table 1 and the validation report is . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.